Dainippon Sumitomo Awakes To The U.S. Market And Buys Sepracor For $2.6 Billion
This article was originally published in The Pink Sheet Daily
Executive Summary
Buying the Lunesta marketer gives the Japanese pharma an experienced U.S. regulatory and commercial team ahead of lurasidone launch.
You may also be interested in...
Dainippon Buys Boston Biomedical To Build On Cancer Strategy
Japanese pharma Dainippon will gain two clinical-stage novel drugs targeting cancer stem cells and a drug-discovery platform with the acquisition of Boston Biomedical for $200 million upfront and substantial milestones.
Dainippon Buys Boston Biomedical To Build On Cancer Strategy
Japanese pharma Dainippon will gain two clinical-stage novel drugs targeting cancer stem cells and a drug-discovery platform with the acquisition of Boston Biomedical for $200 million upfront and substantial milestones.
Cardiac Safety Could Be Distinguishing Point For Sunovion's New Antipsychotic Latuda
Lack of a cardiac safety signal looks to be a key selling point for Sunovion Pharmaceuticals' atypical antipsychotic Latuda (lurasidone).